

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 July 2019 (25.07.2019)



(10) International Publication Number
WO 2019/141549 A1

(51) International Patent Classification:

C07D 487/10 (2006.01) A61P 35/00 (2006.01)
A61K 31/407 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/EP2019/050370

(22) International Filing Date:

09 January 2019 (09.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18461506.0 16 January 2018 (16.01.2018) EP

(71) Applicant: ADAMED PHARMA S.A. [PL/PL]; Mariana Adamkiewiczza 6A, Pienkow, 05-152 Czosnow (PL).

(72) Inventors: FEDER, Marcin; ul. Obrońców Tobruku 19/118, 01-494 Warszawa (PL). MAZUR, Maria; ul. Generała Sylwestra Kaliskiego 45/161, 01-476 Warszawa (PL). KALINOWSKA, Iwona; ul. Skalskiego 3/27, 03-982 Warszawa (PL). JASZCZEWSKA, Joanna; ul. Gen. Ludomila Rayskiego 3/69, 01-307 Warszawa (PL). LEWANDOWSKI, Wojciech; ul. Basniowa 3, 05-600 Grojec (PL). WITKOWSKI, Jakub; ul. Odkryta 65E/10, 03-140 Warszawa (PL). JELEN, Sabina; ul. Rudnickiego 10A/3, 01-858 Warszawa (PL). WOS-LATOSI, Katarzyna; ul. Koscielna Droga 117, 05-092 Lomianki (PL).

(74) Agent: SULIKOWSKI, Daniel; ADMARKA SP. Z O.O., Ul. Mariana Adamkiewiczza 6, Pienkow, 05-152 Czosnow (PL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53



Formula (I)

(57) Abstract: The invention relates to 1,2,3',5'- tetrahydro- 2H- spiro[pyrrolo- 3,1'- pyrrolo[3,4- c]pyrrole]- 2,3'- dione compounds represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of cancer, immune diseases, inflammatory conditions, allergic skin diseases associated with excessive proliferation, blinding disease and viral infections.

WO 2019/141549 A1